FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB:NRGX), a biotech company engaged in the research and development of innovative gene therapies for the brain and central nervous system, announced today that it completed a private placement of an additional $5 million of Series D Convertible Preferred Stock (the “Series D Stock”) at a price of $35 per share. Each share of Series D Stock is convertible into approximately 30.17 shares of common stock.
